key: cord-0946433-wne0n9op
authors: Sessa, Cristiana; Cortes, Jorge; Conte, Pierfranco; Cardoso, Fatima; Choueiri, Toni; Dummer, Reinhardt; Lorusso, Patricia; Ottmann, Oliver; Ryll, Bettina; Mok, Tony; Tempero, Margaret; Comis, Silvia; Oliva, Cristina; Peters, Solange; Tabernero, Josep
title: The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
date: 2021-11-23
journal: ESMO Open
DOI: 10.1016/j.esmoop.2021.100339
sha: 64395e07cfe785b9fbb410da903681d7a9d30b0e
doc_id: 946433
cord_uid: wne0n9op

The COVID-19 pandemic promises to have lasting impacts on cancer clinical trials that could lead to faster patient access to new treatments. In this article, an international panel of oncology experts discusses the lasting impacts of the pandemic on oncology clinical trials and proposes solutions for clinical trial stakeholders, with the support of recent data on worldwide clinical trials collected by IQVIA. These lasting impacts and proposed solutions encompass three topic areas. First, acceleration and implementation of new operational approaches to oncology trials with patient-centric, fully decentralized virtual approaches, that include remote assessments via telemedicine and remote devices. Geographical differences in the uptake of remote technology, including telemedicine, are discussed in the article, focusing on the impact of the local adoption of new operational approaches. Second, innovative clinical trials. The pandemic has highlighted the need for new trial designs that accelerate research and limit risks and burden for patients while driving optimization of clinical trial objectives and endpoints, while testing is being minimized. Areas of considerations for clinical trial stakeholders are discussed in detail. In addition, the COVID-19 pandemic has exposed the underrepresentation of minority groups in clinical trials; the approach for oncology clinical trials to improve generalizability of efficacy and outcomes data is discussed. Third, a new problem-focused collaborative framework between oncology trial stakeholders, including decision makers, to leverage and further accelerate the innovative approaches in clinical research developed during the COVID-19 pandemic. This could shorten timelines for patient access to new treatments by addressing the cultural and technological barriers to adopting new operational approaches and innovative clinical trials. The role of the different stakeholders is described, with the aim of making COVID-19 a catalyst for positive change in oncology clinical research and eventually in cancer care.

The COVID-19 pandemic promises to have lasting impacts on cancer clinical trials, from accelerating the implementation of new operational approaches and innovative clinical trials to a tighter collaboration among all clinical trial stakeholders that could lead to faster patient access to new treatments.

The pandemic has had various impacts on the treatment of cancer patients and oncology clinical trials in different regions and countries (Figure 1 ). 1 The high mortality associated with certain cancers has certainly motivated patients and physicians to continue ongoing treatment. However, patients with non-emergent medical issues were not allowed into some healthcare facilities. There has been a reduction in new cancer diagnoses as people postponed screening procedures; this is likely to cause an increase in advanced-stage diagnoses in the near future ( Figure 2 ).

Data from surveys of key opinion leaders around the world and from internal databases indicate that in oncology trials the accrual of new patients decreased during the COVID-19 pandemic, but to a lesser extent than in non-oncology trials. 2 3 For example, between April 2020 and March 2021, 386 oncology trials were halted, with 274 subsequently reactivated, and 74 remaining stopped (including 38 that were terminated). Error! Bookmark not defined. There have been geographical variations depending on COVID-19 outbreaks and case rates, government policies and implementation of measures to assure the quality of the primary efficacy data and the safety of patients. 4 A minority of oncology trials were terminated or withdrawn, most of which were early phase studies. The most frequent responses to COVID-19 were amending protocols (involving 43% of participants), switching patients to virtual visits (40%), extending patient visit windows (33%) and shipping investigational drugs to patients (27%). 4 Planning has become more difficult due to the reduced availability of health care personnel, who are in high demand due to the pandemic in some regions and to the COVID-19 fluctuations. 5 Overall, during the pandemic there has been a shift in the way clinical trials are executed towards decentralized models. 6 Once an extensive vaccination has been carried out, the current scenario is forecast to improve rapidly; however, the successful new approaches to remote management of patients and studies have paved the way for new ways to practice J o u r n a l P r e -p r o o f oncology and conduct clinical trials. This is encouraging investigators, sponsors, regulatory authorities and others to discuss ways to optimize the conduct of clinical trials. This article reports the results of discussions among an international panel of oncology experts on the lasting impact of the pandemic on oncology clinical trials and proposes solutions for clinical trial stakeholders, with the support of recent data on worldwide clinical trials collected by IQVIA.

Oncology trials can be very demanding for patients and their families in terms of time, travel, costs and stress, which made the decision to participate complicated even prior to concerns about COVID-19. During the pandemic, institutions aimed to limit the time patients spent on their premises by minimizing and streamlining procedures in the sense of unit flow optimization 7 8 9 and replacing in-person visits by remote options. While intended to reduce the risk of COVID infection, these procedures effectively also reduced the burden of care and of clinical trials for patients. Optimizing both the trial design and study conduct from an operational perspective, with more streamlined clinical visits and some visits and treatments occurring in patients' homes, may make participation in clinical trials less burdensome, while expanding the reach of the trial to a broader population. 10 Patient-centric, fully decentralized virtual approaches, where all study components are completed outside of the site, or hybrid formats, where a portion of site-based visits remain while other components are coordinated with patients from their homes, were already being proposed before the pandemic. However, uptake was scarce. Since the pandemic, decentralized trials have been adopted by several clinical programs. Virtual approaches include remote assessments via telemedicine and remote devices, supported J o u r n a l P r e -p r o o f by structured data collection, decentralized data collection with use of laboratories and imaging facilities located close to where patients live. 11 They also include adoption of connected devices, home nursing visits and direct-to-patient drug shipment. 12 Similarly, remote monitoring, with or without centralized monitoring and a risk-based approach, has been promoted and implemented to replace on-site monitoring, again with variations among regulatory agencies related to type of trial and duration. 4 Innovation could be advanced by collaboration among clinical trial stakeholders focusing on validation and acceptance of the following components of virtual and hybrid trials:

Telemedicine 

In IQVIA's experience, most oncology clinical trials could benefit from a hybrid approach rather than a fully virtual solution. The latter is more appropriate for non-interventional investigations such as long-term follow-up studies. 13

While most clinical trials might benefit from new approaches, it is important to assess each study based on factors such as the phase of the study (e.g. early vs. late phase), the mode of action of the drug or intervention being tested, the route of administration (e.g. oral vs. intravenous), the safety and tolerability profile, the patient population, and the study objectives and endpoints.

A recent paper in The Lancet notes that many of the changes made to clinical trials during the pandemic could have been made long ago. 14 The paper quotes Kevin Sheth, chief of neurocritical care and emergency neurology at Yale University, Connecticut, as saying, "Telemedicine technology has been around for 10, 15, 20 years. In many cases, the barriers to incorporating telemedicine more widely into clinical practice really have been in large part administrative and bureaucratic, having to do with cost and reimbursement-not because of some conceptual or technological limitation. The same is true in the clinical research world."

Geographical differences in the uptake of remote technology, including telemedicine, is impacting the local adoption of new operational approaches and may jeopardize site participation in decentralized trials. 15 In Italy, telemedicine between physicians and patients currently involves primarily phone calls and emails, while physician-to-physician consultation includes the sharing of radiologic images such as CT scans, as well as laboratory results. A local oncology or "oncologia territoriale" project is in advanced development to enable a network of family physicians to connect with oncologists about the oncologists' existing patients.

The aim is to avoid the need for these patients to travel to oncology centers for every check-up, and instead to consult with their family physician. However, there are reservations among Italian oncologists about the use of telemedicine directly with patients, due to a belief that successful oncology treatments require development of a personal relationship between physician and patient, which may be hard to create remotely; and those patients might not feel as free to ask questions in a telemedicine setting as in person.

Telemedicine is supported by Italian oncologists only for communicating lab results.

In Asian countries, telemedicine is primarily being used outside of clinical trials at present and is increasing in popularity. Cultural or other barriers, including age, do not appear to be jeopardizing patient acceptance of telemedicine in Asia. Patients typically appreciate the option of communicating with the doctor by phone or video, and the reduced need for travel. Local oncologists suggest that telemedicine should only be paid for if new medical information -for example, from blood tests or imaging -is communicated, which requires a medical consultation.

In the USA, medical licenses are granted on a state-by-state basis, thus limiting the ability to provide telemedicine across state borders within the country. This limits patient access to physicians and trials that they might otherwise reach out to.

The responses from a European patient community (Melanoma Patient Network Europe) to telemedicine have been mixed. Some patients missed the real-world interaction with their treating oncologists, in particular, in the event of bad news. 16 Others in the same situation found it beneficial being able to have a family member beside them, rather than receiving bad news alone due to COVID restrictions on family members at clinic visits. Patients further commented on the dramatically reduced impact on their lives thanks to reduced travel and out-of-pocket expenses such as parking fees. Interestingly, patients also commented on the fact that telecommunication leveled the interaction between them and their oncologist and that they appreciated the scheduled interaction, rather than overrunning consultations or broad callback windows. 17

Remote monitoring relies on availability of appropriate technologies and authorization for private patient data to be used. Local and regional differences can have a strong influence on trial participation for investigators and sites. Regional differences in addressing confidentiality and data safety may create a wide variety of rules for sponsors and monitors to follow, increasing complexity and cost.

In Switzerland, remote monitoring is not currently available due to data protection concerns, and the fact that hospitals do not allow access to patients' medical records from outside their firewalls. In addition, access would be all-or-nothing, with no option to provide access only to defined elements of the chart.

The Swiss Group for Clinical Cancer Research (SAKK) reports that the national regulatory body, Swissmedic, is allowing minimal changes to clinical trials during the pandemic. This is based on guidance issued by both Swissmedic and Swiss Association of Research Ethics Committees (Swissethics) in December 2020 and updated in January 2021. The Swissmedic website notes that, "Remote source data verification of aspects critical for patient safety and data integrity is permitted under certain conditions within the framework of clinical trials with medicinal products in times of the pandemic. Adjustments have also been made to the submission process for reporting/applications due to the current situation." 18 The SAKK perspective is that from an administrative and financial point of view, it is better to remain adherent to approved good clinical practices, since any changes would require extensive human and structural resources. 19 In Italy, very few institutions (an estimated 2 out of 65 Italian clinical sites) currently allow remote monitoring or provide access to electronic health records (EHR). This is due to concerns about patient privacy, less extensive site availability of EHRs than in other countries, and lack of available technology to enable selective sharing of elements of the EHR that are pertinent to a given clinical trial. National efforts are underway to create an oncology EHR network, such as the one led by the Periplo Foundation.

In Spain, the regulatory authorities have granted permission for remote monitoring for COVID-19 related trials and for oncology trials. The implementation rate varies between institutions and among pharmaceutical companies and clinical research organizations (CROs). In Vall d'Hebron Institute of Oncology, remote monitoring has been implemented for around 30% of clinical trials.

In the USA, remote monitoring was available at some institutions pre-COVID, but many institutions did not allow it, due to concerns including the need for offsite access to patient data. During the pandemic, this J o u r n a l P r e -p r o o f mindset changed, and remote monitoring rapidly became the norm at many sites. However, some sites found this approach more difficult to utilize than others, due to rigid contracts that needed to be signed to minimize potential for breaches of patient confidentiality. As many sites are still using remote monitoring due to continued COVID cases and people still working off-site, a hybrid model will likely be developed post-pandemic, where various elements of monitoring are carried out remotely and others, onsite.

The COVID-19 pandemic has driven Real-World Evidence (RWE) uptake in clinical trials in several ways.

There is a need for new trial designs that accelerate research and limit risks and burden for patients, The application of real-world data (RWD) to support drug approvals is not a novel concept, and is accepted by the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and other regulatory agencies. However, RWD has been applied on a limited basis in past years, mostly for rare diseases. 29 In a recent article, Eichler et al 30 explain why the future will not see randomized clinical trials (RCTs) versus RWE, but rather both RCTs and RWE, further stimulating the long-standing debate recently fueled by Collins et al. 31 Areas of consideration for clinical trial stakeholders should include consideration and validation of:

These might include surrogate endpoints for time to progression, duration of response or overall survival, measured using real-world data, such as medication start and stop dates and death records New study designs These could involve protocol simplification and a built-in option to incorporate remote study approaches; common protocols and master/platform studies; and more flexible designs that can adapt quickly and more efficiently to changing environment conditions

These might replace or partially replace placebo or standard-of-care arms to address recruitment challenges for rare conditions or to stimulate participation in clinical trials and overcome patient aversion to placebo or standard of care Simplified eligibility criteria

In line with FDA recommendations on broadening eligibility criteria and avoiding unnecessary exclusion criteria without strong clinical or scientific justification, eligibility criteria should mirror the populations likely to use the intervention, taking into considerations patient insights Inclusive gender, racial and ethnic population

The goal here would be to increase the representativeness of the patient population enrolled in cancer clinical trials Expedited amendments that have direct patient impact and minimized bureaucracy for administrative amendments This would help ensure flexible and rapid adaptation to the changing clinical research environment, including the restrictions and limitations imposed by the pandemic

These could balance the regulatory requirements with the burden of the disease being studied to find an adequate risk:benefit ratio for diseases with high mortality, such COVID-19 and certain cancers Tools aimed at minimizing missing data These might include alternative ways of obtaining elements of missing data e.g., surveys, virtual visits, and e-health data if appropriate, could be leveraged; supplementary analyses using historical clinical trial data or real-world data could support assessment of the impact of missing data elements

These could redefine what is considered relevant to capture and report as a deviation, with aimed at increasing efficiency of trials and J o u r n a l P r e -p r o o f of monitoring, and reducing costs and time spent on activities with little scientific value and no impact on patient safety Digital patient engagement Increased use of digital communication to improve safety by keeping the patient informed and improving communications with healthcare providers, thus reducing the patient burden and increasing retention in clinical trials Table 2 . Areas of consideration for clinical trial stakeholders.

A new collaborative framework between oncology trial stakeholders, including decision makers, could The pandemic has driven improved collaboration among clinical trial stakeholders, e.g. leading to faster approval of protocols by IRBs and regulators and even to faster regulatory approvals (for example, for vaccines), by simplifying and optimizing processes to facilitate innovative research.

Plans to minimize bureaucracy for trial approval and expedite amendments should be further developed.

Since a streamlined global approach is needed, an ideal goal of a single IRB across sites and countries could be pursued through an agreement between regulatory authorities to minimize complexities due to regional requirements.

Since trials need to be designed with the patient as the center of attention, the new collaborative 

Global Oncology Trends: Outlook to 2025. IQVIA Institute for data on clinical trials

Expected Medium-and Long-Term Impact of the COVID-19 Outbreak in Oncology

COVID-19 impact on oncology clinical trials: a 1-year analysis

COVID-19 and Clinical Trials: Past, Present, and Future

Rethinking cancer clinical trials for COVID-19 and beyond

Rethinking Clinical Trials Reform During the COVID-19 Pandemic

Institute for Healthcare Improvement blog, Why COVID-19 Makes Achieving Optimal Patient Flow More Important Than Ever

Adapting to a Pandemic -Conducting Oncology Trials during the SARS-CoV-2 Pandemic

Rapid Implementation of Telemedicine During the COVID-19 Pandemic: Perspectives and Preferences of Patients with Cancer

Impact of COVID-19 on oncology clinical trials

Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff

The Growing Value of RWE. An IQVIA Real World Solutions White Paper 2020

IQVIA data on file

COVID-19 and readjusting clinical trials

Medical Oncology Professionals' Perceptions of Telehealth Video Visits

Patient and Physician Attitudes Toward Telemedicine in Cancer Clinics Following the COVID-19 Pandemic. JCO Clin Cancer Inform

Clinical trials on medicinal products -Pandemic by SARS-CoV-2

Head of Quality Assurance, Regulatory Affairs & Pharmacovigilance at SAAK

testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study

Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City

Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Remdesivir for the Treatment of Covid-19 -Final Report

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Racial Disproportionality in Covid Clinical Trials

Use of Real-world Data for New Drug Applications and Line Extensions

Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth

The Magic of Randomization versus the Myth of Real-World Evidence

European Medicines Agency Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) Pandemic

Food and Drug Administration Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

Perspectives on Oncology-Specific Language During the Coronavirus Disease 2019 Pandemic: A Qualitative Study

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled

Decrease in cancer diagnosis 12 months after the COVID-19 pandemic in Catalonia

The authors thank Jill Dawson, Ph.D., for medical writing assistance.

BR: Consultancy: Amgen, Astra Zeneca, BMS, Celgene, Clinigen, IQVIA, MSD, Novartis, Pfizer and Roche (personal fees). CO: no conflict of interest to disclose. CS: no conflict of interest to disclose. FC 

J o u r n a l P r e -p r o o f